MedPath

Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism

Not Applicable
Completed
Conditions
Cataract
Interventions
Device: LAL (Light Adjustable Lens) and Light Deliver Device (LDD)
Device: Monofocal control IOL
Registration Number
NCT01496066
Lead Sponsor
Calhoun Vision, Inc.
Brief Summary

The purpose is to evaluate the Calhoun Vision Light Adjustable Lens (LAL) and Light Delivery Device (LDD) for reducing astigmatism and improving uncorrected vision after implantation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Undergoing cataract surgery and be willing to have LAL or commercially available IOL implanted
  • Pre-operative regular corneal astigmatism of >= 0.75 diopters and <= 2.0 diopters
  • Best spectacle corrected visual acuity reduced to 20/40 or worse with or without glare
  • Projected best spectacle corrected visual acuity of 20/20 or better
  • Clear intraocular media other than cataract
  • Potentially good vision in fellow eye
  • Fully dilated pupil of >= 7.0 mm
Exclusion Criteria
  • Zonular laxity or dehiscence
  • Pseudoexfoliation
  • Age related macular degeneration
  • Retinal degenerative disorder
  • Diabetes with any evidence of retinopathy
  • Glaucomatous optic neuropathy, uveitis, significant anterior segment pathology, keratoconus
  • Corneal dystrophy, previous corneal or intraocular surgery
  • Complications during cataract surgery
  • Serious co-morbid conditions
  • Systemic medications that my increase UV sensitivity
  • Irregular astigmatism

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LALLAL (Light Adjustable Lens) and Light Deliver Device (LDD)LAL implanted
Monofocal controlMonofocal control IOLMonofocal control IOL implanted
Primary Outcome Measures
NameTimeMethod
Rotation of LAL Landmark Meridian to Anatomical Landmark at Pre-Adjustment and 6 Months Postop6 months

Number (%) of eyes with rotation of LAL meridian of ≤ 5 degrees from Pre-Adjustment to 6 months postop. This endpoint was achieved by taking dilated anterior segment photographs of the LAL at Pre-Adjustment and 6 months postop. The angular difference between a landmark on the LAL and an anatomical landmark on the subjects eye was measured. The same landmarks on the LAL and the subjects eye were used at each time point. The angular difference between the two time points was then determined.

Percent Absolute Reduction in MRSE6 months

Percent absolute reduction in Manifest Refraction Spherical Equivalent (MRSE) from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. It is used to describe an ophthalmic refraction with one number. It is defined as the (sphere)+ 0.5(cylinder). So, if you had a refraction of +1.00-1.00x090 the MRSE would be +0.50, the +1.00 is the sphere and the -1.00 is the cylinder in this example. If you had a refraction of +0.25-1.50x145 the MRSE would be -0.50. The absolute value of the MRSE is taken and its reduction is calculated from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.

Percent Reduction in Manifest Cylinder6 months

Percent reduction in manifest cylinder from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. Manifest cylinder refers to only the astigmatic or cylindrical component of an ophthalmic manifest refraction. For example if someone had a refraction of +0.50-1.00x090, the -1.00 is the manifest cylinder component. The reduction of the manifest cylinder is determined from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.

Secondary Outcome Measures
NameTimeMethod
Uncorrected Visual Acuity 20/20 or Better6 months

Percent of eyes with UCVA of 20/20 or better in the LAL treatment group at 6 months postoperatively was calculated to determine if it is significantly greater than the percent of eyes with UCVA of 20/20 or better in the monofocal control group at 6 months postoperatively.

Mean Reduction in Cylinder by Cylinder Adjustment Stratum (0.75D-1.25D)6 months

Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group. Results were to be evaluated for each cylinder adjustment stratum (0.75-1.25 D and 1.50-2.00 D) separately.

Mean Reduction in Cylinder by Cylinder Adjustment Stratum (>1.25D)6 months

Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to Pre-Adjustment in the LAL group/17-21 days postoperative in the control group.

Mean BSCVA6 months

Mean BSCVA for the "best case" cohort (no macular problems) at 6 months postoperatively was compared between the LAL treatment group and the monofocal control group. Endpoint success was to be achieved if the difference in mean BSCVA between the LAL cohort and the monofocal control group is within 1 line (0.1 LogMAR) (non-inferiority margin or delta).

Percent Absolute Reduction in Manifest Refraction Spherical Equivalent (MRSE) for Eyes With <0.75 D Cylinder Postoperatively6 months

For eyes with \<0.75 D of cylinder at pre-adjustment (LAL)/17-21 days (control group), percent mean absolute reduction in MRSE by subject in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in mean absolute MRSE in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group.

Trial Locations

Locations (17)

Jules Stein Eye Institute

🇺🇸

Los Angeles, California, United States

Arbor Centers for Eye Care

🇺🇸

Orland Park, Illinois, United States

Newsom Eye

🇺🇸

Sebring, Florida, United States

Minnesota Eye Consultants, PA

🇺🇸

Bloomington, Minnesota, United States

Ophthalmology Consultants, Ltd.

🇺🇸

Saint Louis, Missouri, United States

Carolina Vision Center

🇺🇸

Fayetteville, North Carolina, United States

Eye Consultants of Texas

🇺🇸

Grapevine, Texas, United States

Focal Point Vision

🇺🇸

San Antonio, Texas, United States

Hoopes Vision

🇺🇸

Draper, Utah, United States

Wolstan & Goldberg Eye Associates

🇺🇸

Torrance, California, United States

Eye Surgeons of Indiana

🇺🇸

Indianapolis, Indiana, United States

Jones Eye Clinic

🇺🇸

Sioux City, Iowa, United States

Discover Vision & Laser Center

🇺🇸

Leawood, Kansas, United States

Cleveland Eye Clinic

🇺🇸

Brecksville, Ohio, United States

EyeSight Ophthalmic Services, PA

🇺🇸

Somersworth, New Hampshire, United States

Vance Thompson Vision

🇺🇸

Sioux Falls, South Dakota, United States

Vold Vision

🇺🇸

Fayetteville, Arkansas, United States

© Copyright 2025. All Rights Reserved by MedPath